Pipeline Regulation

HUTCHMED clears CMC rejection to win dual China approvals for SYK inhibitor sovleplenib

HUTCHMED (HKEX: 00013; NASDAQ: HCM) won simultaneous NMPA approvals (CXHS2600027, CXHS2600058) on Nov 19, 2026 for SYVIK (sovleplenib) in adult ITP and wAIHA 11 months after an impurity rejection.

HUTCHMED clears CMC rejection to win dual China approvals for SYK inhibitor sovleplenib
China Pharma Desk chart from HUTCHMED HKEX (00013) and SEC Form 6-K filings (November 19, 2026), NMPA approvals CXHS2600027 and CXHS2600058, and ClinicalTrials.gov NCT05029635 / NCT05535933.

HUTCHMED (China) Limited (HKEX: 00013; NASDAQ/AIM: HCM) announced on November 19, 2026 (SEC Form 6-K Exhibit 99.2) that China’s National Medical Products Administration (NMPA) has granted simultaneous marketing approvals for two New Drug Applications of its oral spleen tyrosine kinase (SYK) inhibitor SYVIK (sovleplenib / HMPL-523, Chinese trade name Saiweike): adult chronic primary immune thrombocytopenia (ITP) after an insufficient response to at least one prior therapy (CXHS2600027), and adult warm antibody autoimmune hemolytic anemia (wAIHA) after an insufficient response to prior corticosteroid therapy (CXHS2600058). The dual clearance makes sovleplenib the first SYK inhibitor approved in China and the first oral targeted therapy cleared in the country for wAIHA—completing an 11-month regulatory recovery after a December 30, 2025 NMPA non-approval notice over manufacturing impurity thresholds stalled the original January 2024 ITP filing and prompted HUTCHMED to withdraw its U.S. and European Phase 1 ITP trial (NCT06291415).

While HUTCHMED retains 100% worldwide rights to sovleplenib and secured U.S. Food and Drug Administration (FDA) Orphan Drug Designations for ITP (October 29, 2026) and wAIHA (November 5, 2026), the simultaneous China approvals arrive six days after the November 14 publication of the 2026 National Reimbursement Drug List (NRDL), meaning SYVIK will launch in China as a self-pay and commercial-insurance product throughout 2027 ahead of the mid-2027 NRDL negotiation window.

How a two-indication priority review recovered from the December 2025 impurity rejection

The regulatory trajectory of sovleplenib illustrates both the tightening of Chemistry, Manufacturing, and Controls (CMC) impurity standards at the NMPA’s Center for Drug Evaluation (CDE) and the speed of priority-review resubmissions once analytical and process controls are remediated:

  • Initial ITP filing and December 2025 CMC rejection (CXHS2400006): HUTCHMED submitted its first China NDA for sovleplenib in primary ITP on January 11, 2024 (CNINFO filing 1218850747.PDF) under Priority Review, backed by the Phase 3 ESLIM-01 trial (NCT05029635). After nearly 24 months of review, the NMPA issued a non-approval notice (Yaopin Tongzhijian) on December 30, 2025 because batch impurity limits did not meet tightened CDE specifications.
  • Nine-month resubmission-to-approval sprint (CXHS2600027 & CXHS2600058): After completing CMC impurity-reduction work, HUTCHMED re-qualified for Priority Review on January 8, 2026 and resubmitted the ITP NDA (CXHS2600027) on February 10, 2026. In parallel, following positive Phase 3 topline results in wAIHA (ESLIM-02, NCT05535933) announced on January 7, 2026 and Breakthrough Therapy Designation in March 2026, the CDE accepted the wAIHA NDA (CXHS2600058) with Priority Review on April 29, 2026. The NMPA cleared both applications together on November 19, 2026—9.3 months after the ITP refiling and 6.7 months after the wAIHA acceptance.

Pivotal data across ESLIM-01 (ITP) and ESLIM-02 (wAIHA) against global FcRn, BTK, and SYK benchmarks

Both approved indications are anchored by randomized, double-blind, placebo-controlled Phase 3 trials in China (300 mg oral once daily for 24 weeks) published in The Lancet Haematology and presented at the European Hematology Association (EHA) 2026 Congress (June 12, 2026 filing):

Trial / Indication Design & Baseline Population Primary Endpoint (Durable Response) Overall Response & Onset Rescue Therapy & Key Subgroup Data Grade ≥3 TEAEs & Discontinuations
ESLIM-01 (NCT05029635 / CTR20211537) — Adult Chronic Primary ITP Randomized 2:1 (n = 188: 126 sovleplenib 300 mg QD vs. 62 placebo, 24 wks); median 4 prior lines; 74.6% had prior TPO / TPO-RA 48.4% (61/126) vs. 0% (0/62) (p < 0.0001, platelet count  ≥ 50 × 109/L on  ≥ 4 of 6 scheduled visits in Weeks 14–24) Weeks 0–12 ORR: 68.3% vs. 14.5%; Weeks 0–24 ORR: 70.6% vs. 16.1% (p < 0.0001); median time to response 8 days vs. 30 days Prior  ≥ 4 lines DRR: 47.7% vs. 0%; prior TPO/TPO-RA subgroup DRR: 46.8% vs. 0% (p < 0.0001) Grade  ≥ 3 TEAEs: 25.4% vs. 24.2%; significant improvement in SF-36 physical function and fatigue (p < 0.05)
ESLIM-02 (NCT05535933 / CTR20221854) — Adult Relapsed/Refractory wAIHA Randomized Phase 2/3 (Phase 3 double-blind 24 wks, 300 mg QD vs. placebo in post-glucocorticoid primary or secondary wAIHA) 66% vs. 15% (p < 0.0001, durable hemoglobin response during Weeks 5–24) 24-week ORR (Hb ≥ 100 g/L with  ≥ 20 g/L increase from baseline without rescue): 70% vs. 22% (p < 0.0001); median onset 3.1 weeks vs. 6.3 weeks Rescue therapy required: 16% vs. 54%; RBC transfusion: 11% vs. 43%; steroid/concomitant taper or stop: 50% vs. 15% (p = 0.003); prior rituximab DRR: 69% vs. 16% (p = 0.0022) Grade  ≥ 3 TEAEs: 43% vs. 59% (most common: worsening wAIHA 18% vs. 43%, URI 2% vs. 11%); 0% treatment-related deaths or discontinuations

Placing sovleplenib against global and domestic hematology competitors highlights two distinct commercial dynamics:

  1. In wAIHA, sovleplenib captures an uncontested first-mover position in China: Globally, the only other first-generation SYK inhibitor—Rigel Pharmaceuticals’ (NASDAQ: RIGL) fostamatinib (Tavalisse, approved by the U.S. FDA for ITP in 2018)—failed its Phase 3 FORWARD trial in wAIHA (NCT03764618) in June 2022 after an elevated placebo response in Eastern European sites and has never been approved in China. In the United States, Johnson & Johnson (NYSE: JNJ) won the first FDA targeted approval in wAIHA in August 2026 with its intravenous anti-FcRn antibody nipocalimab (Imaavy), while Sanofi (EPA/NASDAQ: SNY) is advancing its oral BTK inhibitor rilzabrutinib (Wayrilz, FDA-approved for ITP in August 2025) after reporting Phase 2b LUMINA 2 wAIHA data in October 2026. In China, where roughly 40,000 adults live with wAIHA and off-label rituximab, splenectomy, and chronic steroids remain the only options, SYVIK is the first approved targeted therapy of any class.
  2. In ITP, sovleplenib enters a crowded Chinese second-line market but targets the TPO-RA-refractory pool: According to IQVIA figures cited in HUTCHMED’s filings, China has roughly 430,000 prevalent ITP patients and 41,000 new diagnoses annually, with oral TPO receptor agonists—including Hengrui’s (SSE: 600276) hetrombopag (Hengqu), Novartis’s eltrombopag (Revolade), and Fosun Pharma’s avatrombopag (Doptelet)—plus Zai Lab / argenx’s anti-FcRn efgartigimod (Vyvgart) already entrenched in the basic NRDL. Meanwhile, InnoCare Pharma (HKEX: 09969; SSE: 688428) completed its China Phase 3 ITP trial for the BTK inhibitor orelabrutinib (Yinuokai, NCT05124028) and is preparing an sNDA. Sovleplenib’s clinical wedge in ITP is its 46.8% durable response rate (versus 0% on placebo) in the 74.6% of ESLIM-01 patients who had already failed TPO/TPO-RA therapy.

Why HUTCHMED withdrew its U.S./EU sovleplenib trial and signaled a next-generation SYK NCE for out-licensing

For cross-border business development (BD) observers, the most consequential contrast lies between sovleplenib’s domestic commercial launch and its overseas clinical status.

On ClinicalTrials.gov, HUTCHMED’s multicenter U.S., German, Spanish, Norwegian, and Australian Phase 1 trial of HMPL-523 in adult ITP (NCT06291415) is listed as WITHDRAWN with 0 patients enrolled. Because sovleplenib (compound 225 in PCT patent WO2012167733A1) claims an earliest priority window from 2011–2012, the 2024–2025 CMC delay in China compressed the remaining composition-of-matter patent runway outside China before global Phase 3 trials in ITP or wAIHA could even start.

Rather than funding late-stage Western trials on an aging patent clock, HUTCHMED CEO and CSO Weiguo Su, Ph.D., noted during recent investor briefings that the company can advance a new chemical entity (NCE) next-generation SYK inhibitor with full patent life into U.S. and global clinical development—using the clinical validation of ESLIM-01 and ESLIM-02 plus the October and November 2026 FDA Orphan Drug Designations (which confer 7-year U.S. orphan market exclusivity upon approval independently of composition-of-matter patents) to evaluate strategic partnering pathways alongside its emerging Antibody-Targeted Therapy Conjugate (ATTC) oncology platform (HMPL-A251, HMPL-A580, and HMPL-A830).

The next records that will determine SYVIK’s commercial trajectory and global value are initial provincial procurement (guawang) launch pricing in China across 300 mg tablet packs in Q1 2027; whether HUTCHMED prices sovleplenib for entry into the 2027 NRDL negotiation cycle (for effect January 1, 2028) across both ITP and wAIHA simultaneously; and whether the company files a U.S. IND or discloses an ex-China licensing agreement for either orphan-designated sovleplenib in wAIHA or a follow-on SYK new chemical entity in 2027.